Tengion, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNGNQ research report →
Companywww.tengion.com
Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.
- CEO
- David I. Scheer
- IPO
- 2022
- Employees
- 25
- HQ
- Winston-Salem, US
Price Chart
Valuation
- Market Cap
- $4.03K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 188.30%
- ROIC
- -159.36%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,549,000 · -33.51%
- EPS
- $-6.60 · 21.24%
- Op Income
- $-16,597,000
- FCF YoY
- 11.53%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 79.90
- Avg Volume
- 128.78K
Get TickerSpark's AI analysis on TNGNQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TNGNQ Coverage
We haven't published any research on TNGNQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TNGNQ Report →